The canonical profile remains the primary reading view. Read the canonical profile.
We added a plain-language reader guide with cited answers, re-checked FDA’s CJC-1295 evaluation and compounding safety-risk page, and noted that HHS’s October 30, 2026 draft enforcement-discretion policy does not include CJC-1295. 316
What this version reported
FDA staff recommended in 2024 against adding any CJC-1295-related substance to the 503A compounding list, and FDA lists CJC-1295 among substances that may present significant safety risks. CJC-1295 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗
Reader guide in this version
Key takeaway
CJC-1295 is a lab-made 29-amino-acid analogue of growth hormone-releasing hormone (GHRH). FDA treats CJC-1295 and CJC-1295 with drug affinity complex (DAC) as two different active substances.3 It is not an FDA-approved drug. FDA’s 2024 evaluation found that none of five CJC-1295-related substances is a component of an FDA-approved drug, and FDA staff recommended against adding any of them to the list of substances pharmacies may use in compounding.3 Its human data come from small, short studies in healthy adults, and FDA found no data on effectiveness for growth hormone deficiency. A company stopped clinical trials in 2006 after a participant died.3 CJC-1295 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.6
At a glance
- What it is
- A synthetic analogue of growth hormone-releasing hormone, 29 amino acids long. A version with an added drug affinity complex (DAC) binds to albumin in the blood and lasts longer.3
- FDA status
- Not FDA-approved. FDA staff recommended in 2024 against adding any CJC-1295-related substance to the 503A compounding list, and FDA lists CJC-1295 among compounding substances that may present significant safety risks.1,3
- Human evidence
- Small placebo-controlled studies in healthy adults that measured hormone levels. FDA identified no effectiveness data for growth hormone deficiency.3
- Sport status
- FDA’s 2024 evaluation notes that growth hormone secretagogues, including CJC-1295, are prohibited at all times on the World Anti-Doping Agency’s prohibited list.3
- Evidence strength
- Smaller controlled human trials
What is CJC-1295?
CJC-1295 is a lab-made peptide of 29 amino acids modelled on growth hormone-releasing hormone (GHRH), the brain hormone that prompts the pituitary to release growth hormone.3
FDA’s evaluation distinguishes CJC-1295 from CJC-1295 with drug affinity complex (DAC), which carries an added chemical group that binds albumin in the blood. FDA treats them as different active substances, each with salt forms, and says they are not interchangeable.3
FDA reports that CJC-1295 DAC was first described in 2005 by ConjuChem Biotechnologies, and that interest in CJC-1295 on internet forums has grown since then.3
How is CJC-1295 thought to work?
As an analogue of GHRH, CJC-1295 is intended to stimulate the release of growth hormone. FDA states that published studies show CJC-1295 DAC acts as a growth hormone secretagogue in rodents, but it found no studies establishing whether CJC-1295 without DAC is pharmacologically active.3
FDA notes that the DAC modification is thought to extend the peptide’s life in the body by binding albumin, but could also cause it to bind other proteins and have off-target effects.3
What do human studies show?
FDA’s evaluation describes placebo-controlled studies in healthy adults, published in 2006, in which a CJC-1295 DAC substance raised growth hormone and IGF-1 levels for days after a single exposure.3
Across three published studies, FDA counted 63 healthy adults exposed to it, 87% of them men, and 73% received only one exposure. Reactions where it was given were most common; FDA also lists headache, reactions in which blood vessels widen, increased heart rate and low blood pressure.3
FDA describes reports that a 2006 Phase 2 trial in people with HIV lipodystrophy was stopped after a participant had a fatal heart attack, which the attending physician attributed to underlying coronary artery disease. The data from that trial have not been published.3
FDA found no data on effectiveness for growth hormone deficiency and no safety information in children.3
What the evidence base contains
- Controlled human trial Two placebo-controlled studies in healthy adults published in 2006, in which most participants received one or a few exposures to a CJC-1295 DAC substance and growth hormone and IGF-1 levels were measured.3
- Small, short, or incompletely reported human study FDA counted 63 healthy adults, 87% of them men, exposed to a CJC-1295 DAC substance across three published studies; 73% received a single exposure.3
- Animal or laboratory research Animal studies in which a CJC-1295 DAC substance acted as a growth hormone secretagogue, and toxicology studies in rats and dogs that showed bleeding, inflammation and tissue death where it was given.3
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Is CJC-1295 FDA-approved?
No. FDA’s evaluation, dated November 15, 2024, states that none of the five CJC-1295-related substances is a component of an FDA-approved drug, and that there is no United States Pharmacopeia monograph for any of them.3
FDA staff evaluated the five substances for the 503A bulks list, the list of substances that pharmacies may use in compounding, for growth hormone deficiency. They concluded that the balance of criteria weighs against adding any of them, citing poor characterization, unclear history of use, safety concerns from animal studies and a lack of effectiveness data.3
A Federal Register notice announced that FDA’s Pharmacy Compounding Advisory Committee would discuss CJC-1295-related substances at its December 4, 2024 meeting. FDA’s evaluation states that FDA will not issue a final determination until the committee’s input has been considered.3,4
FDA’s compounding safety-risk page, current as of April 22, 2026, lists CJC-1295 among substances whose nominations were withdrawn, citing possible immune reactions, impurities and serious adverse events including increased heart rate.1
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. CJC-1295 is not among them.5,6
Timeline
- CJC-1295 DAC is first described in the scientific literature, according to FDA’s evaluation.3
- ConjuChem withdraws CJC-1295 DAC from clinical trials after a participant’s death, according to FDA’s evaluation.3
- A Federal Register notice announces the December 4, 2024 advisory-committee meeting that will discuss CJC-1295-related substances.4
- FDA staff date their evaluation recommending against adding CJC-1295-related substances to the 503A bulks list.3
- FDA’s Pharmacy Compounding Advisory Committee meets to discuss CJC-1295-related substances.3,4
- FDA’s compounding safety-risk page, as last updated, lists CJC-1295 among withdrawn nominations with safety concerns.1
What is still unknown?
Whether CJC-1295 has any clinical benefit: FDA found no effectiveness data for growth hormone deficiency.3
Its long-term safety, which FDA says is unknown, and its safety in children, for which FDA found no information.3
What is in products sold under the name: FDA found inconsistent naming and notes that it is often unclear which form is meant.3
FDA’s final decision on the 503A list, which was not part of the sources reviewed through November 14, 2026.1,3
Sources for this version
- 1Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 2Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs ↗
U.S. Department of Justice · Official source · Source checked July 22, 2026
- 3FDA evaluation of five CJC-1295-related bulk substances, November 15, 2024 ↗
U.S. Food and Drug Administration · Official source · Source checked September 15, 2026
- 4Federal Register notice 2024-24828 · published 2024-10-25 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List ↗
Federal Register via GovInfo · Official source · Source checked August 21, 2026
- 5Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 6HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026